NCT00405015View on ClinicalTrials.gov

The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

October 31, 2008

Conditions
Ischemia-Reperfusion InjuryThe Metabolic Syndrome
Interventions
DRUG

rosiglitazone

Rosiglitazone 4 mg bidaily for 8 weeks

Trial Locations (1)

6500 HB

Clinical research Center Nijmegen, Nijmegen

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Radboud University Medical Center

OTHER